Craig-Hallum Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $43
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $43.
Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $43.